Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on developing novel complement therapies for neuroinflammatory diseases, has announced the granting of inducement awards to two new non-executive employees. These equity awards, approved on August 15, 2024, were granted under the company's 2022 Employment Inducement Award Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The new employees received options to purchase a total of 83,000 shares of Annexon common stock. These options have a ten-year term and an exercise price of $5.98 per share, which was the closing price of Annexon's stock on the grant date. The options will vest over 4 years, with 25% vesting on the first anniversary and an additional 1/48th vesting monthly thereafter, subject to continued employment.
Annexon, Inc. (Nasdaq: ANNX), un'azienda biopharmaceutica focalizzata nello sviluppo di nuove terapie complementari per le malattie neuroinfiammatorie, ha annunciato il conferimento di premi di incentivazione a due nuovi dipendenti non esecutivi. Questi premi azionari, approvati il 15 agosto 2024, sono stati concessi nell'ambito del Piano di Premi di Incentivazione all'Assunzione del 2022 dell'azienda, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
I nuovi dipendenti hanno ricevuto opzioni per acquistare un totale di 83.000 azioni delle azioni ordinarie di Annexon. Queste opzioni hanno un termine di dieci anni e un prezzo di esercizio di $5,98 per azione, che corrisponde al prezzo di chiusura delle azioni di Annexon alla data di concessione. Le opzioni matureranno in 4 anni, con il 25% che matura il primo anniversario e un ulteriore 1/48 che matura mensilmente successivamente, a condizione che l'impiego continui.
Annexon, Inc. (Nasdaq: ANNX), una empresa biofarmacéutica centrada en el desarrollo de nuevas terapias complementarias para enfermedades neuroinflamatorias, ha anunciado la concesión de premios de incentivos a dos nuevos empleados no ejecutivos. Estos premios de capital, aprobados el 15 de agosto de 2024, se otorgaron bajo el Plan de Premios de Incentivos para el Empleo 2022 de la empresa, cumpliendo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Los nuevos empleados recibieron opciones para comprar un total de 83,000 acciones de acciones comunes de Annexon. Estas opciones tienen un plazo de diez años y un precio de ejercicio de $5.98 por acción, que fue el precio de cierre de las acciones de Annexon en la fecha de concesión. Las opciones se acumularán a lo largo de 4 años, con el 25% acumulándose en el primer aniversario y un 1/48 adicional acumulándose mensualmente a partir de entonces, sujeto a la continuación del empleo.
Annexon, Inc. (Nasdaq: ANNX)는 신경 염증 질환에 대한 새로운 보완 요법 개발에 주력하는 생물 제약 회사로, 두 명의 신규 비상무 직원에게 유인 상금을 부여한다고 발표했습니다. 이 주식 상금은 2024년 8월 15일에 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 회사의 2022 고용 유인 상금 계획에 따라 부여되었습니다.
신규 직원들은 Annexon의 보통주 83,000주를 구매할 수 있는 옵션을 받았습니다. 이 옵션은 10년의 기간을 가지며, 실행 가격은 주당 $5.98로, 이는 부여 날짜에 Annexon 주식의 종가와 같습니다. 옵션은 4년에 걸쳐 지급됩니다, 첫 번째 기념일에 25%가 지급되고 이후 매월 1/48이 추가로 지급되며, 이는 지속적인 고용 조건에 따릅니다.
Annexon, Inc. (Nasdaq: ANNX), une entreprise biopharmaceutique axée sur le développement de nouvelles thérapies complémentaires pour les maladies neuro-inflammatoires, a annoncé l'octroi de récompenses d'incitation à deux nouveaux employés non exécutifs. Ces récompenses en actions, approuvées le 15 août 2024, ont été attribuées dans le cadre du Plan d'Attribution de Récompenses d'Incitation à l'Emploi 2022 de l'entreprise, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Les nouveaux employés ont reçu des options pour acheter au total 83 000 actions des actions ordinaires d'Annexon. Ces options ont une durée de dix ans et un prix d'exercice de 5,98 USD par action, ce qui correspondait au prix de clôture des actions d'Annexon à la date d'octroi. Les options s'acquitteront sur 4 ans, avec 25% s'acquittant au premier anniversaire et 1/48 supplémentaire s'acquittant mensuellement par la suite, sous réserve d'une poursuite de l'emploi.
Annexon, Inc. (Nasdaq: ANNX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Komplementtherapien für neuroinflammatorische Erkrankungen konzentriert, hat die Gewährung von Anreizprämien an zwei neue nicht-executive Mitarbeiter bekannt gegeben. Diese Aktienprämien, die am 15. August 2024 genehmigt wurden, wurden im Rahmen des Unternehmensplans für Beschäftigungsanreize von 2022 gewährt, in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4).
Die neuen Mitarbeiter erhielten Optionen zum Kauf von insgesamt 83.000 Aktien des Stammkapitals von Annexon. Diese Optionen haben eine Laufzeit von zehn Jahren und einen Ausübungspreis von 5,98 USD pro Aktie, was dem Schlusskurs der Annexon-Aktie am Tag der Gewährung entspricht. Die Optionen reif werden über einen Zeitraum von 4 Jahren, wobei 25 % am ersten Jahrestag und anschließend monatlich 1/48 anreifenden, vorausgesetzt, die Anstellung bleibt bestehen.
- Annexon is attracting new talent to support its growth and development efforts
- The company has a structured employee incentive program in place to align employee interests with shareholders
- None.
BRISBANE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the new non-executive employees received options to purchase 83,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Annexon’s novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré syndrome, Huntington’s disease and geographic atrophy, Annexon is rigorously advancing its mid-to late-stage clinical trials to bring their potential treatments to patients as quickly as possible. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
How many new employees received inducement grants from Annexon (ANNX) on August 15, 2024?
What is the total number of Annexon (ANNX) stock options granted to the new employees?
What is the exercise price of the stock options granted by Annexon (ANNX) on August 15, 2024?
What is the vesting schedule for the stock options granted by Annexon (ANNX) to new employees?
